Guide | How Rh Incompatibility Affects the Fetus: A Complete Prevention Guide
When the father is Rh-positive and the mother is Rh-negative, expectant parents should understand Rh disease of the newborn and how it can be prevented during pregnancy.
The Rh factor is a protein on red blood cells, and most people are Rh-positive. If an Rh-negative mother carries an Rh-positive fetus, delivery or another event that mixes maternal and fetal blood—such as placental complications, ectopic pregnancy, miscarriage, or amniocentesis—may cause her immune system to produce anti-Rh antibodies. In a later pregnancy, these antibodies can cross the placenta and destroy fetal red blood cells, causing anemia, jaundice, or even fetal death. A first pregnancy is usually at lower risk, but later Rh-positive fetuses may face hemolytic disease.
Prevention is key. Research and clinical experience show that giving anti-Rh immunoglobulin, sold as RhoGAM, to an Rh-negative mother soon after delivery can neutralize fetal red blood cells that entered her circulation and prevent immune sensitization. Experts recommend a preventive injection at about 28 weeks and another after delivery. These antibodies do not cross the placenta and do not harm the fetus.
Once the mother is sensitized, however, RhoGAM cannot reverse it. Any procedure that may mix maternal and fetal blood, such as amniocentesis, should be performed by an experienced physician who avoids passing through the placenta where possible.
Whether the fetus is Rh-positive depends on the father’s genotype. If he has two positive genes (homozygous), the child will be Rh-positive. If he is heterozygous, with one positive and one negative gene, the fetus has a 50% chance of being Rh-positive. Fetal Rh status is usually not confirmed until after delivery unless amniocentesis is performed, but that test carries a small sensitization risk.
Although RhoGAM is a blood product, experts emphasize its strong safety record, with no recorded transmission of HIV or hepatitis. Rare sensitization may still occur after an injection, but the overall benefits far outweigh the potential risks. All Rh-negative pregnant women should discuss this fully with their obstetrician and accurately report previous RhoGAM injections during prenatal visits and blood testing to avoid misinterpretation.
Guide | How Rh Incompatibility Affects the Fetus: A Complete Prevention Guide
Guide | How Rh Incompatibility Affects the Fetus: A Complete Prevention Guide
When the father is Rh-positive and the mother is Rh-negative, expectant parents should understand Rh disease of the newborn and how it can be prevented during pregnancy.
The Rh factor is a protein on red blood cells, and most people are Rh-positive. If an Rh-negative mother carries an Rh-positive fetus, delivery or another event that mixes maternal and fetal blood—such as placental complications, ectopic pregnancy, miscarriage, or amniocentesis—may cause her immune system to produce anti-Rh antibodies. In a later pregnancy, these antibodies can cross the placenta and destroy fetal red blood cells, causing anemia, jaundice, or even fetal death. A first pregnancy is usually at lower risk, but later Rh-positive fetuses may face hemolytic disease.
Prevention is key. Research and clinical experience show that giving anti-Rh immunoglobulin, sold as RhoGAM, to an Rh-negative mother soon after delivery can neutralize fetal red blood cells that entered her circulation and prevent immune sensitization. Experts recommend a preventive injection at about 28 weeks and another after delivery. These antibodies do not cross the placenta and do not harm the fetus.
Once the mother is sensitized, however, RhoGAM cannot reverse it. Any procedure that may mix maternal and fetal blood, such as amniocentesis, should be performed by an experienced physician who avoids passing through the placenta where possible.
Whether the fetus is Rh-positive depends on the father’s genotype. If he has two positive genes (homozygous), the child will be Rh-positive. If he is heterozygous, with one positive and one negative gene, the fetus has a 50% chance of being Rh-positive. Fetal Rh status is usually not confirmed until after delivery unless amniocentesis is performed, but that test carries a small sensitization risk.
Although RhoGAM is a blood product, experts emphasize its strong safety record, with no recorded transmission of HIV or hepatitis. Rare sensitization may still occur after an injection, but the overall benefits far outweigh the potential risks. All Rh-negative pregnant women should discuss this fully with their obstetrician and accurately report previous RhoGAM injections during prenatal visits and blood testing to avoid misinterpretation.
Source:
Collected online